Consensus on the statin of choice in patients with impaired glucose metabolism: results of the DIANA study
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Millán Núñez-Cortés, Jesúsca
- dc.contributor.author Cases Amenós, Aleixca
- dc.contributor.author Ascaso Gimilio, Juan Franciscoca
- dc.contributor.author Barrios Alonso, Vivencioca
- dc.contributor.author Pascual Fuster, Vicenteca
- dc.contributor.author Pedro-Botet, Juan Carlosca
- dc.contributor.author Pintó Sala, Xavierca
- dc.contributor.author Serrano Cumplido, Adalbertoca
- dc.date.accessioned 2017-11-15T08:40:35Z
- dc.date.available 2017-11-15T08:40:35Z
- dc.date.issued 2017
- dc.description.abstract INTRODUCTION AND OBJECTIVES: Despite the recognized clinical benefit of statins on cardiovascular prevention, providing correct management of hypercholesterolaemia, possible adverse effects of their use cannot be disregarded. Previously published data shows that there is a risk of developing diabetes mellitus or experiencing changes in glucose metabolism in statin-treated patients. The possible determining factors are the drug characteristics (potency, dose), patient characteristics (kidney function, age, cardiovascular risk and polypharmacy because of multiple disorders) and the pre-diabetic state. METHODS: In order to ascertain the opinion of the experts (primary care physicians and other specialists with experience in the management of this type of patient) we conducted a Delphi study to evaluate the consensus rate on diverse aspects related to the diabetogenicity of different statins, and the factors that influence their choice. RESULTS: Consensus was highly significant concerning aspects such as the varying diabetogenicity profiles of different statins, as some of them do not significantly worsen glucose metabolism. There was an almost unanimous consensus that pitavastatin is the safest statin in this regard. CONCLUSIONS: Factors to consider in the choice of a statin regarding its diabetogenicity are the dose and patient-related factors: age, cardiovascular risk, diabetes risk and baseline metabolic parameters (which must be monitored during the treatment), as well as kidney function.
- dc.format.mimetype application/pdfca
- dc.identifier.citation Millán Núñez-Cortés J, Cases Amenós A, Ascaso Gimilio JF, Barrios Alonso V, Pascual Fuster V, Pedro-Botet Montoya JC. Et al. Consensus on the statin of choice in patients with impaired glucose metabolism: results of the DIANA study. Am J Cardiovasc Drugs. 2017 Apr;17(2):135-142. DOI: 10.1007/s40256-016-0197-9
- dc.identifier.doi http://dx.doi.org/10.1007/s40256-016-0197-9
- dc.identifier.issn 1175-3277
- dc.identifier.uri http://hdl.handle.net/10230/33226
- dc.language.iso eng
- dc.publisher SpringerOpenca
- dc.relation.ispartof American Journal of Cardiovascular Drugs. 2017 Apr;17(2):135-42
- dc.rights This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.subject.keyword Diabetes
- dc.subject.keyword Impaired glucose tolerance Consensus
- dc.subject.keyword Statins
- dc.subject.other Diabetis -- Tractament
- dc.title Consensus on the statin of choice in patients with impaired glucose metabolism: results of the DIANA studyca
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion